Botanix (BOT)

Research Collaboration with University of Queensland Institute for Molecular Bioscience in relation to BTX 1801

Analyst | Michael Eidne

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Spec Buy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current Price</td>
<td>$0.105</td>
</tr>
<tr>
<td>Valuation</td>
<td>$0.20</td>
</tr>
<tr>
<td>Market Cap</td>
<td>$75.7m</td>
</tr>
</tbody>
</table>

Quick Read

BOT has received funding from the Australian Government to undertake a research collaboration with the University of Queensland Institute for Molecular Bioscience to study the effectiveness of its Cannabidiol (CBD) based compound, BTX 1801, as an antimicrobial agent with a particular focus on drug-resistant bacteria. If the research project has a positive outcome, the impact on BOT could be material as drug-resistant bacteria in skin disease is a major issue because very few new compounds have been developed to combat the mounting resistance bacteria have to current treatments. We maintain our Speculative Buy recommendation and a $0.20 valuation.

Event | Positive

BOT’s laboratory testing has shown that CBD has antimicrobial properties: BOT announced on the 2nd of July that laboratory testing had shown that Cannabidiol (CBD) displayed antimicrobial properties which may have the potential to be used against anti-biotic resistant skin infections. Based on these findings, BOT is in the process of developing a new CBD based compound, BTX 1801, to target skin infections.

BOT has been awarded an Innovation Connections Grant from the Australian Government: The Australian Government has awarded BOT an Innovation Connections Grant to further investigate these findings in collaboration with the University of Queensland Institute for Molecular Bioscience. The research will be led by Professor Matt Cooper and Dr Mark Blaskovich who are experts in the field of antimicrobial drug discovery and development. The group they lead is aptly called the Centre for Super Bug Solutions (CSS). Their particular focus is on antimicrobial resistance and CSS has a library of antimicrobial resistant microorganisms as well as more common microorganisms that can be used to test the effectiveness of BTX 1801 combined with Permetrex®. The CSS scientists are of the view that while CBD shows interesting preliminary results, it will be key to determine the effect CBD has on drug-resistant bacteria and to determine if the bacteria rapidly develops resistance to CBD once exposed to BTX 1801. CSS is an independent organisation, and the funding is from the Australian Government which will make the results independent of BOT initial findings.

Results from this study will help determine the design of a potential clinical study: CSS plan to test CBD on drug-resistant bacteria and more common bacteria, and the results will help determine whether BTX 1801 will then be further tested in a clinical trial. The data from this study will then be used to design the clinical trial and its end points.

The discovery of a new antibiotic compound would be an important milestone for BOT: All bacteria develop resistance to antibiotics over time, but the issue is that not enough new compounds have been developed to replace those that have lost their efficacy over time. If BTX 1801 is proven to be effective anti-biotic, especially if it is effective against drug-resistant bacteria and bacteria treated with BTX 1801 do not rapidly develop resistance to CBD, BTX 1801 has the potential to be a blockbuster drug. BOT’s suite of CBD based treatments would be very attractive for big pharma. Novartis recently acquired an Atopic Dermatitis treatment for US$111m and a potential US$1 billion in milestones payments and royalties. The treatment is still in the trial phase and has yet to receive FDA approval. This deal demonstrates the potential for BOT’s products if the ongoing laboratory studies and clinical studies are successful.
Our View

The research collaboration and funding by the Australian Government is a positive development for the Company because BOT is having its findings verified by an independent scientific authority. The ability of CBD to impact drug resistance bacteria in skin disease is an important claim that needs to independently proven as the potential ramifications of a new skin treatment for drug-resistant bacteria would be significant. A successful new treatment with the CBD safety profile would be a very valuable asset for BOT and in our view will attract the attention of big pharma.

Recommendation

We maintain our Speculative Buy recommendation and a $0.20 valuation.
RESEARCH:

Ian Christie | Director, Industrial Research
+61 8 9224 6872 ichristie@argonaut.com

Matthew Keane | Director, Metals & Mining Research
+61 8 9224 6890 mkeane@argonaut.com

James Wilson | Analyst, Metals & Mining Research
+61 8 9224 6835 jwilson@argonaut.com

Helen Lau | Analyst, Metals & Mining Research
+852 3557 4804 hlau@argonaut.com

Michael Eilde | Director, Research
+61 8 9224 6831 meidne@argonaut.com

INSTITUTIONAL SALES – PERTH:

Chris Wipp | Executive Director, Head of Sales & Research
+61 8 9224 6875 cwipp@argonaut.com

Damian Rooney | Director Institutional Sales
+61 8 9224 6862 drooney@argonaut.com

John Santal | Consultant, Sales & Research
+61 8 9224 6878 jsantul@argonaut.com

Ben Willoughby | Institutional Dealer
+61 8 9224 6876 bwilloughby@argonaut.com

Josh Welch | Institutional Dealer
+61 8 9224 6859 jwelch@argonaut.com

George Ogilvie | Institutional Dealer
+61 8 9224 6871 gogilvie@argonaut.com

INSTITUTIONAL SALES – HONG KONG:

Damian Rooney | Director Institutional Sales
+61 8 9224 6862 drooney@argonaut.com

CORPORATE AND PRIVATE CLIENT SALES:

Glen Colgan | Managing Director, Desk Manager
+61 8 9224 6874 gcogan@argonaut.com

Kevin Johnson | Executive Director, Corporate Stockbroking
+61 8 9224 6880 kjohnson@argonaut.com

James McGlew | Executive Director, Corporate Stockbroking
+61 8 9224 6860 jmcglew@argonaut.com

Ian Dorrington | Director, Corporate Stockbroking
+61 8 9224 6865 idorrington@argonaut.com

Geoff Barnes-Johnson | Senior Dealer, Corporate Stockbroking
+61 8 9224 6854 gbjohnson@argonaut.com

Rob Healy | Dealer, Private Clients
+61 8 9224 6873 rhealy@argonaut.com

Cameron Prunster | Dealer, Private Clients
+61 8 9224 6853 cprunster@argonaut.com

James Massey | Dealer, Private Clients
+61 8 9224 6849 jmassey@argonaut.com

Chris Hill | Dealer, Private Clients
+61 8 9224 6830 chill@argonaut.com

Important Disclosures

Argonaut acted as Joint Lead Manager to the Placement that raised $15.0M in February 2018 and received fees commensurate with this service. Argonaut acted as Joint Lead Manager to the Placement that raised $8.0M in June 2018 and received fees commensurate with this service. Argonaut holds or controls 12.1M BOT Options exercisable at $0.03 on or before 30 June 2019.

Information Disclosure

Each research analyst of this material certifies that the views expressed in this research material accurately reflect the analyst’s personal views about the subject securities and listed corporations. None of the listed corporations reviewed or any third party has provided or agreed to provide any compensation or other benefits in connection with this material to any of the analyst(s).

For U.S. persons only

This research report is a product of Argonaut Securities Pty Limited, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Argonaut Securities Pty Limited only to “Major Institutional Investors” as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Argonaut Securities Pty Limited has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. (“Marco Polo”). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker-dealer.

Hong Kong Distribution Disclosure

This material is being distributed in Hong Kong by Argonaut Securities (Asia) Limited which is licensed (AXO 052) and regulated by the Hong Kong Securities and Futures Commission. Further information on any of the securities mentioned in this material may be obtained on request, and for this purpose, persons in the Hong Kong office should be contacted at Argonaut Securities (Asia) Limited of Unit 701, 7/F, Henley Building, 5 Queen’s Road Central, Hong Kong, telephone (852) 3557 4800.

General Disclosure and Disclaimer

This research has been prepared by Argonaut Securities Pty Limited (ABN 72 108 330 650) (“ASPL”) or by Argonaut Securities (Asia) Limited (“ASAL”) for the use of the clients of ASPL, ASAL and other related bodies corporate (the “Argonaut Group”) and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this report in any way. ASPL is a holder of an Australian Financial Services License No. 274099 and is a Market Participant of the Australian Stock Exchange Limited. ASAL has a licence (AXO 052) to Deal and Advise in Securities and Advise on Corporate Finances and is a Member of the Hong Kong Stock Exchange Limited. ASAL has a licence (AXO 052) to Deal and Advise in Securities and Advise on Corporate Finance in Hong Kong and is a holder of an Australian Financial Services License No. 274099 and is a Market Participant of the Australian Stock Exchange Limited.

Nothing in this report should be construed as personal financial product advice for the purposes of Section 766B of the Corporations Act 2001 (Cth). This report does not consider any of your objectives, financial situation or needs. The report may contain general financial product advice and you should therefore consider the appropriateness of the advice having regard to your situation. We recommend you obtain financial, legal and taxation advice before making any financial investment decision.

This research is based on information obtained from sources believed to be reliable and ASPL and ASAL have made every effort to ensure the information in this report is accurate, but we do not make any representation or warranty that it is accurate, reliable, complete or up to date. The Argonaut Group accepts no obligation to correct or update the information or the opinions in it. Opinions expressed are subject to change without notice and accurately reflect the analyst(s)’ personal views at the time of writing. No member of the Argonaut Group or its respective employees, agents or consultants accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research.

Nothing in this research shall be construed as a solicitation to buy or sell any financial product, or to engage in or refrain from engaging in any transaction. The Argonaut Group and/or its associates, including ASPL, ASAL, officers or employees may have interests in the financial products or a relationship with the issuer of the financial products referred to in this report by acting in various roles including as investment banker, underwriter or dealer, holder of principal positions, broker, director or adviser. Further, they may buy or sell those securities as principal or agent, and as such may effect transactions which are not consistent with the recommendations (if any) in this research. The Argonaut Group and/or its associates, including ASPL and ASAL, may receive fees, brokerage or commissions for acting in those capacities and the reader should assume that this is the case.
There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment.

The analyst(s) principally responsible for the preparation of this research may receive compensation based on ASPL’s and / or ASAL’s overall revenues.

Copyright
© 2018. All rights reserved. No part of this document may be reproduced or distributed in any manner without the written permission of Argonaut Securities Pty Limited and / or Argonaut Securities (Asia) Limited. Argonaut Securities Pty Limited and Argonaut Securities (Asia) Limited specifically prohibits the re-distribution of this document, via the internet or otherwise, and accepts no liability whatsoever for the actions of third parties in this respect.